Acasti Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Acasti Pharma announced that CEO Jan D’Alvise will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting September 13, 2021, at 7:00 AM ET. Acasti focuses on innovative drug delivery technologies for rare diseases, with three lead clinical assets holding Orphan Drug Designation by the FDA. These assets target conditions like Subarachnoid Hemorrhage, Ataxia-telangiectasia, and Postherpetic Neuralgia, providing significant marketing exclusivity and patent protection.
- None.
- None.
LAVAL, Québec, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announced that Jan D’Alvise, President and Chief Executive Officer of Acasti Pharma, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021.
Acasti’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021, at 7:00 AM Eastern Time.
The webcast can be accessed here and on the investor relations section of Acasti’s website at https://www.acastipharma.com/en/investors as of Monday, September 13, 2021, at 7:00 AM Eastern Time. Management will also be participating in one-on-one meetings with qualified members of the investor community throughout the conference.
About Acasti
Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. Acasti’s novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery—all which could help to increase treatment compliance and improve patient outcomes.
Acasti’s three lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provide the assets with seven years of marketing exclusivity post-launch in the United States and protection by over 40 granted and pending patents. The lead assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability, for which no treatment currently exists; and (iii) GTX-101, a topical spray, targeting Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years. For more information, please visit: https://www.acastipharma.com/en.
Neither NASDAQ, the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Acasti Contact:
Jan D’Alvise
Chief Executive Officer
Tel: 450-686-4555
Email: info@acastipharma.com
www.acastipharma.com
Investor Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ACST@crescendo-ir.com
FAQ
What is the date for Acasti Pharma's presentation at the H.C. Wainwright Conference?
How can I access Acasti Pharma's presentation from the conference?
What are the main focuses of Acasti Pharma's clinical assets?
What designation have Acasti Pharma's lead clinical assets received?
What is the significance of the Orphan Drug Designation for Acasti Pharma?
